Mechanisms of cell sensitization to α radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Supiot, Stephane ^a,b   Gouard, Sebastien ^a   Charrier, Josiane ^b   Apostolidis, Christos ^c   Chatal, Jean Francois ^a,b   Barbet, Jacques ^a   Davodeau, François ^a   Cherel, Michel ^a,b  

^a INSERM   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISMUTH 213; CYCLOHEXYLDIETHYLENETRIAMINEPENTAACETIC ACID; DNA; DOXORUBICIN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B B4; PACLITAXEL; PENTETIC ACID DERIVATIVE; RADIOISOTOPE; SYNDECAN 1; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL SURVIVAL; CHEMOSENSITIVITY; COMET ASSAY; CONFERENCE PAPER; DNA CONTENT; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; G2 PHASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MULTIPLE MYELOMA; PACLITAXEL; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 26444577554     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0021     Document Type: Conference Paper

References (34)

1. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
2. 213Bi. Br J Cancer 1999;80: 175-84.
3. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294: 1537-40.
4. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 1994; 54:3506-10.
5. Milas L, Saito Y, Hunter N, Milross CG, Mason KA. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 1996; 40:163-70.
6. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
7. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 1990;57:55-64.
8. Byfield JE, Lee YC, Tu L. Molecular interactions between Adriamycin and X-ray damage in mammalian tumor cells. Int J Cancer 1977;19:186-93.
9. Durand RE, LePard NE. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol 1997;42:171-9.
10. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
11. Supiot S, Rio E, Gouard S, et al. α-Radioimmunotherapy of multiple myeloma could be improved by concomitant chemotherapy, 4814. In: San Francisco, California: 93rd annual meeting of the American Association for Cancer Research; 2002 April 6-10. p. 972.
12. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94: 318-23.
13. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans- cyclohexyldiethylnenetriaminepenta-acetic acid for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans 1992;1:1173-8.
14. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
15. 225Ac-immunoconjugates. Nucl Med Commun 1995;16:468-76.
16. Koester SK, Roth P, Mikulka WR, Schlossman SF, Zhang C, Bolton WE. Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7. Cytometry 1997;29:306-12.
17. Alapetite C, Wachter T, Sage E, Moustacchi E. Use of the alkaline comet assay to detect DNA repair deficiencies in human fibroblasts exposed to UVC, UVB, UVA and γ-rays. Int J Radiat Biol 1996;69:359-69.
18. Zhang C, Ao Z, Seth A, Schlossman SF. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol 1996;157:3980-7.
19. Bussing A, Vervecken W, Wagner M, Wagner B, Pfuller U, Schietzel M. Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry 1999;37:133-9.
20. Koester SK, Schlossman SF, Zhang C, Decker SJ, Bolton WE. APO2.7 defines a shared apoptotic-necrotic pathway in a breast tumor hypoxia model. Cytometry 1998;33:324-32.
21. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16:1664-7.
22. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29:450-74.
23. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-7.
24. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003;101:3136-41.
25. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-204.
26. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21.
27. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14.
28. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
29. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995; 92:4507-11.
30. Kroning R, Lichtenstein A. Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis. Leuk Res 1998;22:275-86.
31. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998; 13:839-48.
32. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002;277:44317-26.
33. 213Bi-α radioimmunotherapy for multiple myeloma. Clin Cancer Res 1999;5:3165-70s.
34. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.